Biotech company Revvity Inc. (RVTY) has recently been the subject of several financial developments. Notably, Insider Joel S. Goldberg has sold 3,500 shares of Revvity stock, while other trading activities involved Tidal Investments LLC, Advisors Asset Management Inc, and other institutions. Strong demand for its diagnostic products has boosted company profit and sales, even leading to a quarterly dividend declaration by the board. Revvity also exceeded Q2 2024 earnings estimates, with earnings standing strong amid market challenges. However, a 25% loss over the last three years underscored some financial hardship for investors. Regardless of this, the firm still managed to secure a new 52-week high on an analyst upgrade. Amidst sign of a revenue decline, Revvity lifted annual profit outlook thanks to a strong Q2 performance. The company's shares, currently largely controlled by institutional shareholders, received a rating of 'Moderate Buy' from brokerages. Meanwhile, Revvity is set to release its quarterly earnings soon and has recently announced FY24 earnings guidance.
Revvity RVTY News Analytics from Tue, 09 May 2023 07:00:00 GMT to Fri, 09 Aug 2024 20:49:55 GMT - Rating 6 - Innovation 3 - Information 8 - Rumor 4
